Utilization of Targeted Therapies in Metastatic Colorectal Cancer: An Evidence-Based Approach to Management

As the second leading cause of cancer deaths, colorectal cancer (CRC) remains a major health problem in the United States. Although up to 90% of these tumors are curable if treated at early stages, a significant number of patients are not diagnosed with CRC until it has metastasized. Clearly, the need for improved screening and early detection is critical. Additionally, there continues to be a need for improved strategies to manage patients with metastatic disease. In recent years, advances in our understanding of tumor biology have resulted in the development of targeted therapies and increased attention to the role of molecular markers. This has allowed practitioners to employ more individualized approaches in their treatment of patients with advanced CRC. This program will review the use of molecular markers, evaluate the treatment options available, and summarize the management of the most common treatment-related adverse events to advance the knowledge of health care providers caring for patients with metastatic colorectal cancer.

Available until October 31, 2012.
Physicians: 1.0 AMA PRA Category 1 Credit^™
Nurses: 1.0 contact hour

This activity is sponsored by Quintiles Medical Education, Inc.

This activity is co-provided by Global Education Group and Quintiles Medical Education, Inc.